Background Young people (aged 0-18 years) have been disproportionately aff ected by pandemic infl uenza A H1N1 infection. We aimed to analyse paediatric mortality to inform clinical and public health policies for future infl uenza seasons and pandemics.
Introduction
Seasonal infl uenza can cause infection and treatment in hospital in children, but mortality is low and the viruses predominantly aff ect people older than 65 years of age. 1 However, children have been disproportionately aff ected by pandemic infl uenza A H1N1 compared with older age-groups, 2 and this infection has caused severe disease and death in a minority of children. 3, 4 Despite national and global reports of the complications of pandemic infl uenza A H1N1, a detailed analysis of paediatric mortality has not been provided. Following the outset of the pandemic in England in April, 2009, we initiated a confi dential investigation into all resulting deaths. 5 This investigation has provided a real-time and comprehensive system of national surveillance, which we have used to examine paediatric deaths in depth. We aimed to provide important evidence to strengthen clinical and public health policies for children during forthcoming infl uenza seasons and future pandemics.
Methods

Study population
Mandatory daily reporting systems were established for all suspected and confi rmed deaths from pandemic infl uenza A H1N1 in England. Further deaths were identifi ed through cross-checking of records held by the Regional Directors of Public Health and by the Health Protection Agency's infl uenza reference centres. For all reported cases, a member of the Chief Medical Offi cer's clinical team contacted the responsible senior physician to obtain further details. A death was confi rmed as related to pandemic infl uenza A H1N1 if there was laboratory evidence of H1N1 infection or if H1N1 infection (or synonym) was recorded on the death certifi cate. Further details of the method of death ascertainment have been reported previously. 5 
Study design
All validated deaths in children aged less than 18 years were extracted from this dataset. The clinician responsible for each individual child was interviewed by telephone by a paediatrician working for the Chief Medical Offi cer. The data collection proforma is available in the web appendix. Information gathered included: demographic characteristics, pre-existing disorders and past medical history, and presenting symptoms and clinical course. If results of microbiological, haematological, and radio logical investigations were not immediately available from clinicians, they were obtained from hospital or public health laboratories. Information was cross-checked with coroners' reports. In cases for whom past medical information was unavailable, supplementary information was obtained from the general practitioner or local hospital. When the presence or absence of a symptom or pre-existing disorder was not specifi ed, we assumed that none was present.
Collection and processing of data was undertaken under the Health Service (Control Of Patient Information) Regulations 2002 (Statutory Instrument 1438) for the purpose of communicable disease control in England. Therefore, consent from patients was not needed.
The primary outcome measures were population mortality rates (by age-group and for children with preexisting disorders) and case-fatality rates. Secondary measures included presenting symptoms and signs, preexisting disorders, and subsequent com plications.
The physical status classifi cation scale of the American Society of Anaesthesiologists 6 was used to establish the general health of the children before acute illness. Children were classifi ed as being healthy (grade one) or having mild (grade two), moderate (grade three), or severe (grade four or fi ve) pre-existing systemic disease. Specifi c pre-existing disorders (eg, developmental delay) and the severity of presenting symptoms (eg, dyspnoea) were classifi ed as absent, mild, moderate, or severe by the clinicians who cared for the child.
Recurrent hospital admission was defi ned as an inpatient stay for longer than 6 weeks, or greater than four admissions in the previous year. Bacterial sepsis was confi rmed if bacterial growth was identifi ed on laboratory culture after clinical suspicion of bacterial infection. Bacterial sepsis was presumed by clinicians if systemic features of bacterial infection were present (ie, rising infl ammatory markers or signs of focal infection) but bacterial cultures were negative.
Age-stratifi ed cases of pandemic infl uenza A H1N1 were estimated every week by the Health Protection Agency with methods described previously. 5 Population numbers for England by age-group and ethnic origin are estimated by the Offi ce for National Statistics. The most recent estimates were used to provide denominators for population mortality rates stratifi ed by age 7 and ethnic origin. 8 To assess the risk of death associated with pre-existing disorders that would confer an increased risk of seasonal infl uenza, data from the Department of Health vaccine monitoring system were used to estimate the number of people in England aff ected by these disorders. This system uses primary care records to estimate the number of patients with specifi c grouped disorders by age band. These estimates are available only for children aged at least 6 months. Deaths in those aged less than 6 months were therefore excluded from this analysis.
Statistical analyses
Case-fatality rates were calculated for every age-group with Health Protection Agency midpoint case estimates. The upper and lower estimates by age were used to calculate lower and upper estimates for the case-fatality rates, respectively. A 95% confi dence interval was calculated around these estimates, to account for the uncertainty around the number of cases. The case-fatality 
Role of the funding source
This work was done as part of the Department of Health's public health response to the infl uenza pandemic in England. No additional funding was sought. The funding source had no direct involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. Both authors had full access to all the data in the study and the corresponding author had fi nal responsibility for the decision to submit for publication.
Results
A total of 70 paediatric deaths related to pandemic infl uenza A H1N1 occurred in England during the study period (fi gure). All cases were laboratory confi rmed. Complete demographic and clinical details were obtained for all deaths. Deaths were evenly distributed between male (31) and female (39) children. Median age at death was 7 years (range 0•25-17 years; IQR 2-12 years). Casefatality and population mortality rates were highest in children aged less than 1 year ( Predominantly respiratory symptoms were reported on presentation in 53 of 70 (76%) deaths. Fever, cough, and dyspnoea were the most frequent symptoms on presentation (table 2). The extent of dyspnoea was rated by clinicians as moderate in 28 (40%) and severe in 12 (17%) deaths. Mainly gastrointestinal symptoms were described in two (3%) deaths. Among hospital deaths, most cases (42 of 67; 63%) initially presented to the emergency department with symptoms of infl uenza and 16 (24%) presented in cardiorespiratory arrest. The rest presented in shock (fi ve; 7%), status epilepticus (three; 4%), or with non-specifi c symptoms (one; 1%).
Deaths were categorised into those who deteriorated rapidly and died before, or at the point of, hospital admission (early deaths [19 of 70; 27%]), and those who died after hospital admission (late deaths [51; 73%]). The early deaths group had a signifi cantly greater proportion of children with no, or mild, pre-existing disorders (table 3) . Of the early deaths, nine of 19 (47%) had consulted a general practitioner during their illness.
Before presentation, fever (47 of 51 vs 13 of 19, p=0•020 [Fisher's test]) and dyspnoea (40 of 51 vs six of 19, p=0•002) were more common among late deaths than among early deaths. Nausea and vomiting were less common among late deaths (seven of 51 vs seven of 19, p=0·045). Frequency of other symptoms did not diff er between the two groups.
Children with severe pre-existing disorders accounted for 64% (45 of 70) of deaths. However, 21% (15 of 70) of children who died were previously healthy. Mild preexisting disorders were present in 3% (two) of deaths and moderate disorders in 11% (eight) of deaths. For those with data available, 36% (23 of 62) had a history of recurrent hospital admissions. For most deaths in children aged less than 2 years, moderate or severe preexisting disorders had been reported (87%; 13 of 15). In those older than 2 years, 73% (40 of 55) had moderate or severe pre-existing disorders.
Chronic neurological, gastrointestinal, or respiratory disease were all present in more than half of all deaths ( Death rates from pandemic infl uenza A H1N1 for children with pre-existing disorders were higher than for healthy children. Chronic neurological disease and kidney disease conferred the highest risk of any of the disorders studied (table 5). The absence of denominator data prevented the calculation of an age-standardised mortality rate for gastrointestinal disease. Two children with severe underlying disorders received the pandemic infl uenza A H1N1 vaccine 48 h before developing their terminal illness. No other child was vaccinated against pandemic infl uenza A H1N1.
Median duration from symptom onset to admission (or death if not formally admitted to hospital) was 2 days (IQR 1-5). Five children with inter-current infection contracted during long-term hospital stays were not included in this calculation. Median time from symptom onset to death was 7•5 days (IQR 3-13). Of the children who died, 40 were admitted to critical care units (38 to intensive care; two to high-dependency units). Of these, 27 were transferred from other hospitals for specialist care. Transfer to critical care occurred a median of 1 day (IQR 0-2) after hospital admission. In the children admitted to critical care, death occurred a median of 6 days later (IQR 2-11). Within the hospital, the critical care facility was most commonly the place of death (40 of 67; 60%), followed by the emergency department (17 of 67; 25%).
Organ failure occurred frequently. 40 (57%) children developed respiratory failure that needed mechanical ventilation: seven needed non-invasive ventilation, ten invasive positive pressure ventilation, 21 high-frequency oscillation, and two extra-corporeal membrane oxygenation. High ventilation pressures were usually needed and pneumothoraces occurred in six of the 40 (15%) children, all of whom had insertion of a chest drain. Intracerebral haemorrhage arose secondary to extracorporeal membrane oxygenation in one child. Circulatory failure needing inotropic support occurred in 30 of 70 (43%) children. Acute renal failure necessitated renal replacement therapy (haemofi ltration or haemodialysis) in fi ve of 70 (7%) children. Acute haematological abnormalities were recorded in 25 (36%) children before death. These abnormalities were thrombocytopenia (16; 23%), lymphopenia (14; 20%), neutrophilia (three; 4%), neutropenia (two; 3%), pancytopenia (two; 3%), and disseminated intravascular coagulation (two; 3% Death certifi cates were available for 66 cases. In 46 (70%) cases, pandemic infl uenza A H1N1 or a synonym was recorded as the direct cause of death. In seven (11%) cases, pandemic infl uenza A H1N1 or a synonym was recorded as contributing to death. There was no record of pandemic infl uenza A H1N1 on 13 death certifi cates; in fi ve of which, positive virological test results were received after the death certifi cate was issued.
Discussion
Our report of the 70 deaths in children in England related to pandemic infl uenza A H1N1 has shown that mortality disproportionately aff ects ethnic minorities and those with pre-existing disorders. Many deaths occurred before hospital admission, especially in healthy children or those with only mild pre-existing disorders.
The overall childhood mortality rate for pandemic infl uenza A H1N1 reported here (six per million population) is close to that for the Netherlands (fi ve per million population for children under 14 years 9 ) but lower than that in Argentina (11 per million population). 3 A high disease burden was reported in the southern hemisphere because the pandemic coincided with the infl uenza season in that region. Delayed presentation and unrecognised illness might have contributed further to the high mortality rate in Argentina. 3 Mortality from seasonal infl uenza in children is lower than that reported for pandemic infl uenza A H1N1. Extrapolated data from population mortality estimates in England show a mortality rate from seasonal infl uenza of two per million population for children aged less than 14 years, 10 which is much the same as for international estimates. 11 The occurrence of 70 deaths from pandemic infl uenza A H1N1 in children in 1 year in England is greater than the number of deaths in children every year from leukaemia, and this high childhood mortality was last seen for a single infectious disease (meningococcal disease) in 2001. 12 We identifi ed the highest population mortality and case-fatality rates in children aged less than 1 year. A similar pattern has been reported from other countries. 3 The high population mortality rates that we identifi ed among Bangladeshi and Pakistani groups are consistent with a US report that ethnic minority groups were disproportionately aff ected by severe illness. 13 This fi nding might be attributable to clustering of pandemic infl uenza A H1N1 cases in areas of England with high ethnic minority populations (such as London and the West Midlands), 2 although other areas with lower ethnic minority populations such as the East Midlands and Yorkshire were also greatly aff ected. An increased occurrence of pre-existing disorders might exist in ethnic minority children, although no reliable data are available to assess this claim. The extent to which ethnic origin itself, through genetic or cultural factors, confers increased susceptibility to severe illness or death remains unclear, and further investigation is needed.
We identifi ed two distinct clinical patterns for deaths in children from pandemic infl uenza A H1N1. The fi rst group had early deterioration with death before hospital admission-mainly children with no or mild pre-existing disorders. Although these patients had not presented late to medical services, the threshold for hospital admission of these children is likely to have been higher than for those with severe pre-existing disorders. These children might have been cared for at home in the expectation that their illness would be self-limiting. Children dying early did not have more co-existing bacterial infection than those who died later, implying that these children had severe acute viral infection. A fulminant course has previously been described in a cohort of children with pandemic infl uenza A H1N1 infection who were admitted to critical care after presenting with shock. 14 The mechanism of organ failure in these children is unclear. However, they did have a substantially greater frequency of nausea or vomiting at or before presentation, which could indicate extensive viral replication, leading to early deterioration and death. [15] [16] [17] The second group of deaths was children with severe underlying disorders who deteriorated during hospital admission. Those with neurological disease, particularly cerebral palsy, were at high risk, as described in the USA. 4 However, we also noted a high frequency of gastro-oesophageal refl ux, gastrostomy feeding, and unsafe swallowing (when patients do not have a protective gag refl ex) that frequently co-exist with severe cerebral palsy. The increased risk associated with chronic neurological disease might be explained partly by secondary aspiration and low respiratory reserves in these children. Because of small case numbers and no denominator data, the relative risk of death for cerebral palsy in the absence and presence of associated respiratory and gastrointestinal complications could not be assessed. Good-quality data for chronic disease prevalence derived from the National Health Service primary care services enabled the calculation of disease-specifi c mortality rates. Our analysis showed the highest population mortality rate in children with chronic neurological disease, consistent with the high proportion of children with neurological disease among the deaths. However, although absolute numbers of deaths from chronic kidney disease were low, the population rate of death was fairly high (although with wide confi dence intervals) because of a low population prevalence.
We noted that asthma was present in only 7% of paediatric deaths. The prevalence of childhood asthma in England is estimated at up to 14%. 18 Other investigators have suggested that asthma is associated with increased mortality from pandemic infl uenza A H1N1 in children 3 and adults. 9 Our fi ndings contradict this notion. Although there were deaths in children with asthma, the high population prevalence of asthma will lower the diseasespecifi c mortality rate. An explanation for our observa tions might be that asthma does not increase the risk of death. Alternatively, there might have been a low threshold for admission and aggressive therapy in these patients because of clinical and parental concern; this explanation is lent support by the high numbers of children with asthma who were admitted to hospital and critical care during the pandemic. 3, 19 If this explanation is true, a wider use of early aggressive treatment measures could reduce mortality.
Our study confi rms that most children who died presented with typical respiratory symptoms rather than atypical features that could aid prognosis. Thrombocytopenia and relative lymphopenia, however, might be early predictors of severe illness in children, which lends support to similar fi ndings in adults 20 and children treated in hospital. 21 Confi rmed bacterial infection was present in 20% of cases in our study-mainly pneumonia, which is in accord with data for this pandemic in the USA 4 and for seasonal infl uenza, 22 with similar pathogens described. Early treatment with antibiotics in children with clinical deterioration is important. 23 Only 10% of children in this study received antiviral therapy within 48 h of symptom onset, which is a similar number to reports from Argentina in children treated in hospital.
3 Antiviral use for the treatment of infl uenza in children is controversial. 24 However, these drugs are most eff ective if given within 48 h of symptom onset. 25 Our fi ndings suggest that children with pre-existing disorders are at an increased risk of death. For many of these children, antiviral therapies are one of only a few therapeutic options available if the children are not vaccinated. Although our study was not designed to assess antiviral use, early treatment with antiviral therapy might maximise the eff ectiveness of this treatment. This approach is especially important in primary care because 27% of children in our study died before admission to hospital. Further investigation into the contribution of pre-hospital antivirals to the outcome of aff ected children is needed.
Our fi ndings support the vaccination of children against pandemic infl uenza A H1N1. Children at greatest risk of severe illness or death should be prioritised. Our data indicate that risk groups include children with preexisting illness (including chronic neurological or gastrointestinal disease) and those in ethnic minority groups (including Bangladeshi and Pakistani children). However, our fi ndings also suggest that protection cannot be confi ned to risk groups as 21% of deaths in our cohort occurred in healthy children.
Complete death ascertainment is diffi cult to achieve. However, we believe our reporting system achieved a high level. We have classifi ed deaths according to those occurring before and subsequent to inpatient admission. This classifi cation will not capture deaths occurring within hours of hospital admission; therefore, the true early death group might be larger. By using formal hospital admission, we have been able to examine deaths occurring too rapidly to enable stabilisation.
Case-fatality rates are subject to limitations. 5 Case estimates in England take into account laboratoryconfi rmed cases in primary care, in addition to estimates of the proportion of symptomatic individuals who do not seek medical attention. The estimates of case fatality in this study have wide ranges, indicating uncertainty about those not seeking medical help. If this proportion is higher than estimated, our case-fatality rates might be an overestimate. However, this method of case estimation is likely to provide a more meaningful denominator for case fatality than use of laboratory-confi rmed cases.
Few countries hold comprehensive prevalence data for chronic diseases in the population. The National Health Service has a strong primary care system and a longstanding vaccination programme that relies on pooled data for the occurrence of risk factors. Although these data are derived from a sample of clinical practices, we believe that they provide reliable estimates of prevalence. Additionally, we have interpreted derived mortality rates comparatively rather than in absolute terms. More extensive comparisons of risk would be possible with a control group.
Although this is a large study of paediatric deaths related to pandemic infl uenza A H1N1, more detailed analysis would be possible with higher case numbers. An international study that pooled data on childhood deaths from pandemic infl uenza A H1N1 would be greatly informative.
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